Fig 1. Frequency and phenotype analysis of peripheral pDCs in
pSS patients.
a: The frequency of peripheral pDCs in untreated patients with
pSS or SLE, pSS patients treated with HCQ and matched HC (HC: n=29;
untreated pSS: n=31; pSS treated with HCQ: n=17; untreated SLE: n=9).b: Comparison of activation markers (Mean Fluorescence
Intensity, MFI) on the surface of pDCs between pSS (n=12) and HCs
(n=12). Comparison of TLR7 (n=8) and TLR9 (n=6) expression levels
between pDCs from pSS and HC without stimulation (c, d) and
activated by TLR7 agonist (e) or TLR9 agonist (f) for
6 hours with 100ng/ml IL3 (n=6). Data are shown as mean ± SEM. Unpaired
two-tailed Student’s t-test was applied. *P-value < 0.05,
**P-value < 0.01, ***P-value <0.001, **** P-value
<0.0001.